Abstract Library

#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Strosberg J

Authors: Al-Toubah T, Cives M, Anaya D, Soares H, Strosberg J,

Keywords: GEP-NET, locoregional treatment, ablation, embolization, surgical resection, neuroendocrine tumor, systemic therapy, external beam radiation,

#782 Appendix Well-Differentiated Neuroendocrine Tumors (A-WDNETs) at a Large Tertiary Center: Clinical-Pathological Features and Long-Term Follow-Up Evaluation

Introduction: A-WDNETs comprise 32-57% of appendix tumors, diagnosed incidentally in 0.3-0.9% appendectomies (AP). Overall survival is good, but malignant behavior remains controversial.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Preto J

Authors: Preto J, Vinagre J, Pinto-de-Sousa J, Costa-Maia J, Soares P,

Keywords: NET, well-differentiated, appendix,

#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal

Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Soares M, Inês M, Contente M,

Keywords: Sunitinib, pancreatic neuroendocrine tumors, cost-effectiveness, Portugal,

#362 Succinate Dehydrogenase (SDH) Complex Expression in Pancreatic Endocrine Tumours (PETs)

Introduction: Absence of SDH subunit D (SDHD) mutations were reported by Perren et al (Oncogene 2002) but loss of heterozigosity (LOH) was described in 29% of the PETs. Since SDHD gene may depict a form of genomic imprinting in neuroendocrine (NE) tissue, the reported LOH may drive activation of the hypoxia pathway. Taking advantage from the immunohistochemical (IHC) method for genetic triage we may deduce the mutational status of SDH subunits (A, B, C and D) based on IHC SDHB expression. These subunits are striking candidates as they are mutated in other NE neoplasias.

Conference:

Presenting Author:

Authors: Vinagre J, Preto J, Soares P, Lopes J,

Keywords: PETs SDH LOH,

#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Soares C, Bettencourt H, Preto J, Soares P, Pinto-de-Sousa J,

Keywords: gastroenteropancreatic neuroendocrine tumors, angiogenesis, microvessel density, CD105, Endoglin,